Ventoux Biosciences

Ventoux Biosciences is working to transform treatment for Dupuytren’s and related, under-served, immuno-fibrotic diseases. Founded by a Dupuytren’s patient and propelled by a team with Dupuytren's and fibrosis expertise from bench to bedside – we seek to revolutionize current treatment options via development of novel, first-line, disease-modifying, non-surgical options for patients. Dupuytren's is a chronic, progressive, debilitating and often painful fibrosis of the hands and is >3x more prevalent than Rheumatoid Arthritis. However; no cure and no approved disease slowing agents exist. Unlike RA, surgery remains as the standard of care for Dupuytren's patients. Following positive anti-fibrotic data in an established scleroderma / dermal fibrosis model, we are working to advance our lead candidate VEN-201 to human studies. Our business strategy is to expedite treatment for patients by leveraging expedited FDA clinical & regulatory pathways. Dupuytren's impacts ~265m patients across 7 major markets and upwards of 10 million patients in the U.S. alone. VEN-201 represents a potential novel, differentiated, first-line treatment to slow disease progression and help patients maintain hand function and delay potential progression to surgery or surgical interventions.